Please assess the completion status of the following clinical trial:

Trial Title: Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD according to GOLD criteria (FEV1/FVC\<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)~* Age ≥ 18 years~* Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started~* Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period~* Informed consent~Exclusion Criteria:~* Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.~* Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.~* Pregnant or lactating women.~* Allergy to macrolides.~* Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).~* Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.~* Presence of a malignancy which is clinically active.~* Bronchiectasis.~* Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.~* Heart failure.~* Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: ACTIVE_COMPARATOR): Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this group will receive 3 times a week placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).